← Leaderboards
John Malcolm Hollingsworth
University Of Michigan At Ann Arbor
$8,254,178
Attributed
$11,772,229
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,223,510 · 4
AHRQ$5,888,055 · 4
By mechanism
R01$11,158,657 · 6
K08$613,572 · 1
U2C$339,336 · 1
Top collaborators
- Vahakn B Shahinian11 shared
- Richard A Hirth8 shared
- James Douglas Engel1 shared
- Subramaniam Pennathur1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Eric R. Fearon$27,558,344
- Subramaniam Pennathur$11,719,201
- Douglas Earl Schaubel$12,013,133
- Vahakn B Shahinian$9,253,721
- Stephen A. Eklund$506,491
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationAmericanCostCaringAffectProviderMedicareHealthcareHealth Care CostsResourcesComorbidityAcuteProceduresPatient SubsetsSavingsMedicare ClaimPaymentBeneficiaryPreventionFutureComparative EffectivenessAdverse EventCitratesData Sources
Grant awards (30)
Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysis$660,010
R01 · FY2025 · DK
Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysis$633,610
R01 · FY2024 · DK
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$546,833
R01 · FY2024 · DK
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$399,999
R01 · FY2024 · HS
Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysis$674,010
R01 · FY2023 · DK
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$590,232
R01 · FY2023 · DK
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$399,999
R01 · FY2023 · HS
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$608,867
R01 · FY2022 · DK
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$399,999
R01 · FY2022 · HS
University of Michigan Kidney, Urology and Hematology Research Training Network$339,336
U2C · FY2022 · DK
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$626,445
R01 · FY2021 · DK · contact PI
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$455,125
R01 · FY2021 · AG · contact PI
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$400,000
R01 · FY2021 · HS
Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones$646,069
R01 · FY2020 · DK · contact PI
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients$442,973
R01 · FY2020 · AG · contact PI
Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysis$400,000
R01 · FY2020 · HS
Assessing the Effects of Accountable Care Organizations on Surgical Spending and Quality$347,557
R01 · FY2020 · HS · contact PI
Will the Reach of ACOs Extend to Specialty Care?$321,506
R01 · FY2020 · HS · contact PI
Assessing the Effects of Accountable Care Organizations on Surgical Spending and Quality$313,911
R01 · FY2019 · HS · contact PI
Will the Reach of ACOs Extend to Specialty Care?$298,995
R01 · FY2019 · HS · contact PI
Assessing the Effects of Accountable Care Organizations on Surgical Spending and Quality$317,243
R01 · FY2018 · HS · contact PI
Will the Reach of ACOs Extend to Specialty Care?$309,521
R01 · FY2018 · HS · contact PI
Assessing the Effects of Accountable Care Organizations on Surgical Spending and Quality$371,281
R01 · FY2017 · HS · contact PI
Will the Reach of ACOs Extend to Specialty Care?$305,782
R01 · FY2017 · HS · contact PI
Assessing the Effects of Accountable Care Organizations on Surgical Spending and Quality$366,940
R01 · FY2016 · HS · contact PI
Will the Reach of ACOs Extend to Specialty Care?$321,750
R01 · FY2016 · HS · contact PI
Effects of Physician Social Networks on Surgical Quality, Safety, and Costs$155,104
K08 · FY2015 · HS · contact PI
Effects of Physician Social Networks on Surgical Quality, Safety, and Costs$152,836
K08 · FY2014 · HS · contact PI
Effects of Physician Social Networks on Surgical Quality, Safety, and Costs$152,796
K08 · FY2013 · HS · contact PI
Effects of Physician Social Networks on Surgical Quality, Safety, and Costs$152,836
K08 · FY2012 · HS · contact PI